1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRobert F. Vizza Clinical Accelerator Initiative is sponsored by Lustgarten Foundation. The Clinical Accelerator Initiative (CAI) advances the mission of the Lustgarten Foundation by accelerating the translation of research discoveries into the clinic.
Get alerted about grants like this
Get emailed when new opportunities from “Lustgarten Foundation” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
LOI: Clinical Accelerator Initiative (CAI) Letter of Intent: Clinical Accelerator Initiative (CAI) Letter of Intent (LOI) submissions are due November 2, 2026 Submissions must be through ProposalCentral LOI Submission Deadline : November 2, 2026 Invitations Extended for TAG Presentations: by January 2027 Invitations Extended for Grant Applications: by March 2027 Award Notifications: by July 2027 The purpose of the Dr. Robert F.
Vizza Clinical Accelerator Initiative (CAI) is to advance the mission of the Lustgarten Foundation by accelerating the translation of research discoveries into clinical trials.
Through the CAI, the Lustgarten Foundation will provide academic, clinical researchers the opportunity to propose science-driven concepts seeking to advance the development of new therapies for pancreatic cancer patients while furthering our understanding of disease biology.
The CAI is meant to support trials concepts that are: Innovative and highly collaborative Based on strong pre-clinical and/or clinical scientific rationale Utilizing deep, translational analyses to demonstrate on-target drug mechanism(s) of action and hypotheses around disease biology Advancing the development of novel therapies for pancreatic cancer patients with plans for continuation, if successful The CAI is not meant to support trials concepts that are: Incremental, first-in-human safety or dose-finding studies Irrelevant to the mission of the Lustgarten Foundation and without the goal of advancing the development of novel therapeutic approaches for pancreatic cancer patients II.
Qualifications and Requirements of Research Investigator(s) Applicants must hold an M. D. , D.
M. D. , D.
V. M. , Ph.
D. , or equivalent degree and have a faculty position or equivalent at a college, university, medical institution, or other research facility. Proposals may be submitted by domestic and foreign non-profit or public organizations, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
There are no citizenship requirements for this program.
Research Investigator(s) funded through the CAI typically: Are leading significant pancreatic cancer and/or relevant focus area research Have a demonstrated track record of significant contributions to the field as evidenced by publications, peer-reviewed funding and an ability to advance projects to clinical impact Are willing to interact and/or collaborate with researchers at outside institutions including the Lustgarten Translational Advisory Group and other Lustgarten Foundation-Funded Investigators III.
Funding and Governance While the budget and duration of funding will be dependent on the needs of each trial, CAI trials are typically funded up to a total budget of $1. 5M – $2M over a period of up to 3 years, inclusive of deep translational analyses and indirect costs.
Indirect costs may not exceed a maximum of 10% of direct costs Funded investigators will be expected to interact routinely with the Lustgarten Foundation and associated Translational Advisory Group. Continued funding throughout the project will be dependent on timely receipt of bi-annual progress reports and annual financial reports.
Clinical and translational data generated from CAI trials will be ingested into the Lustgarten Foundation Clinical Information Database (LUCID) The CAI uses a multi-step application process beginning with submission of an LOI through ProposalCentral. Successful LOI submissions will be invited to present their trial concept, rationale, and design to the Lustgarten Foundation Translational Advisory Group (TAG).
Successful presenters will then be invited to submit a full CAI grant application which will be reviewed competitively by a panel of expert peer reviewers. V. Questions regarding this Request for Proposals should be directed to: Program Scientist, Research Tell us a little more about yourself:
According to the current listing, eligibility includes: Researchers and institutions focused on translating pancreatic cancer research discoveries into clinical applications. Emphasis on collaborative and science-driven studies. Confirm the full requirements in the official notice before applying.
Applications for Robert F. Vizza Clinical Accelerator Initiative are due November 2, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Robert F. Vizza Clinical Accelerator Initiative is funded by Lustgarten Foundation. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.